#Vienna #Austria #Lung Cancer #Coreline Soft #AVIEW

Coreline Soft Presents an Innovative Approach to Lung Cancer Screening at ECR 2025

Coreline Soft, a leader in medical AI technology, is set to make a striking impression at the European Congress of Radiology (ECR) 2025, held at the Austria Center Vienna from February 26 to March 2. This prestigious event, recognized as Europe’s leading radiology conference, will see participation from radiologists and medical device firms worldwide. Notably, Coreline Soft will showcase its completely revamped AVIEW product lineup, featuring its flagship model AVIEW (LCS Plus) at booth 107.

As the urgency for lung cancer screening escalates across various European countries, Coreline Soft has been at the forefront of developing AI diagnostic tools that enhance workflow efficiency and facilitate large-scale screening. The launch of AVIEW, which incorporates the advanced capabilities gained from extensive prior research and real-world applications, is a leap forward in the fight against lung cancer.

The latest iteration of AVIEW has been engineered to deliver optimal efficiency, underpinned by robust security frameworks and consistent stability. Significant improvements to the user interface ensure that essential information can be swiftly accessed and utilized, coupled with innovative enhancements in communication functionalities.

The Role of AI in Lung Cancer Screening

The integration of AI into diagnostic processes is proving to be transformative, especially highlighted by collaborations in landmark projects funded by the European Union. Coreline Soft is already recognized for its effective management of AI-based imaging data on cloud platforms, having demonstrated its proficiency within various European cancer screening initiatives.

With successful implementations in the German lung cancer screening project (HANSE) and the Italian project (RISP), the efficacy of AI as a primary diagnostic instrument has been validated. Impressively, the recently released AVIEW LCS has been recognized for its potential utility as a first-read tool in lung cancer screening, as documented in the European Journal of Cancer.

Coreline Soft is not just focusing on technological superiority; it is also emphasizing the importance of collaboration in achieving screening objectives. The experience gained from several European projects enables them to advocate for smoother and more integrated workflows powered by AI innovations, which are becoming essential competitive advantages in the healthcare arena.

Market Impact and Future Plans

Following the success of the German screening project, authorities in Germany have officially recommended AI as a mandatory primary diagnostic tool for lung cancer screening. Similar trends are emerging in other major European markets like France, indicating a shift in the paradigm of how lung cancer is diagnosed and approached at a population level.

Coreline Soft has ambitious plans to broaden its market influence with rigorous compliance to regulatory standards such as the General Data Protection Regulation (GDPR). Jason (Junghyuck) Suh, the Overseas Business Director of Coreline Soft, remarked, "With our optimal AI solution, we aim to enhance precision, speed, and collaboration in lung cancer detection, aligning with the growing demand for AI-driven diagnostics across Europe."

In conclusion, the introduction of AVIEW at ECR 2025 marks a significant advancement in lung cancer screening. With AI redefining traditional diagnostic methods, Coreline Soft is positioned to lead this transformation, driving better health outcomes across Europe and beyond. The future of lung cancer detection is indeed bright, thanks to these innovations that blend cutting-edge technology with clinical expertise.